According to Blueprint Medicines 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.0381. At the end of 2022 the company had a P/E ratio of -4.69.
Year | P/E ratio | Change |
---|---|---|
2022 | -4.69 | -51.97% |
2021 | -9.76 | -148.45% |
2020 | 20.1 | -283.48% |
2019 | -11.0 | 9.92% |
2018 | -9.98 | -48.5% |
2017 | -19.4 | 82.45% |
2016 | -10.6 | -2.52% |
2015 | -10.9 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | -5.49 | -45.35% | ๐บ๐ธ USA |
![]() | -6.22 | -38.01% | ๐บ๐ธ USA |
![]() | -1.21 | -87.92% | ๐บ๐ธ USA |
![]() | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.